Researchers used a model that assumed an inadequate colon prep rate of 25 percent for the standard group and 5 percent for those who used the Pure-Vu. They used 2017 Medicare reimbursement data as a baseline.
Researchers then conducted a cost-minimization analysis considering the lifetime cost and incidence rate of a colonoscopy performed with the Pure-Vu system against a standard colonoscopy.
For high-risk patients, the Pure-Vu System:
- Reduced colorectal cancer incidence rate by 36 percent
- Minimized overall patient costs by up to $3,400 for private payers and up to $1,600 for Medicare beneficiaries
- Reduced the costs of repeated procedures attributable to inadequate prep by $804 for private payers and $951 for Medicare beneficiaries
The research was presented at Digestive Disease Week, June 2 to June 5 in Washington, D.C.
More articles on gastroenterology:
How to keep new patients coming in: 5 physician referral strategies for ASCs
ASC coding tip of the day: Collect every last penny
Medical device makers ‘shocked and disappointed’ by Trump’s proposed $50B tariffs — 5 insights
